"10.1371_journal.pone.0090485","plos one","2014-03-06T00:00:00Z","Jonathan Z Li; Brad Chapman; Patrick Charlebois; Oliver Hofmann; Brian Weiner; Alyssa J Porter; Reshmi Samuel; Saran Vardhanabhuti; Lu Zheng; Joseph Eron; Babafemi Taiwo; Michael C Zody; Matthew R Henn; Daniel R Kuritzkes; Winston Hide; and the ACTG A5262 Study Team","Division of Infectious Diseases, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Harvard School of Public Health, Boston, Massachusetts, United States of America; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America; Department of Virology, University of KwaZulu-Natal, National Health Laboratory Service, Durban, South Africa; Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United States of America; Division of Infectious Diseases, Northwestern University, Chicago, Illinois, United States of America","Â¶ Membership of the ACTG A5262 Study Team is provided in the Acknowledgments.","Dr. Li has served as a consultant for Therapy Edge, Quest Diagnostics, and SeraCare Life Sciences. Dr. Kuritzkes has served as a consultant to and/or has received research grant support from Abbott, Avexa, Bristol-Myers Squibb, Boehringer-Ingelheim, Gilead, GlaxoSmithKline, Merck, Roche, Tobira, Vertex, ViroStatistics, and ViiV Healthcare; he has also received speaking honoraria from Gilead and Roche. No other potential conflicts of interest relevant to this article were reported.","2014","03","Jonathan Z Li","JZL",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
